ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Faculty Opinions recommendation of Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.726438889.793525325
◽
2016
◽
Author(s):
Stefan Bielack
Keyword(s):
Open Label
◽
Phase 3
◽
Open Label Phase
Download Full-text
Related Documents
Cited By
References
Faculty Opinions recommendation of Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.718006635.793477611
◽
2013
◽
Author(s):
Ian Beales
Keyword(s):
Gastric Cancer
◽
Advanced Gastric Cancer
◽
Open Label
◽
Phase 3
◽
Open Label Phase
Download Full-text
Faculty Opinions recommendation of Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.726356324.793557555
◽
2019
◽
Author(s):
Jose Biller
Keyword(s):
Acute Stroke
◽
Antiplatelet Therapy
◽
Standard Care
◽
Platelet Transfusion
◽
Cerebral Haemorrhage
◽
Open Label
◽
Phase 3
◽
Open Label Phase
Download Full-text
Faculty Opinions recommendation of Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.736682352.793578124
◽
2020
◽
Author(s):
Jaffer Ajani
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Squamous Cell
◽
Oesophageal Squamous Cell Carcinoma
◽
Open Label
◽
Phase 3
◽
Open Label Phase
Download Full-text
Faculty Opinions recommendation of Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.736675072.793566801
◽
2019
◽
Author(s):
Pedro Legua Leiva
Keyword(s):
Single Dose
◽
Multiple Dose
◽
Strongyloides Stercoralis
◽
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Superiority Trial
◽
Randomised Controlled
Download Full-text
Faculty Opinions recommendation of Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.737782327.793577733
◽
2020
◽
Author(s):
Diana English
◽
Andrea Buras
Keyword(s):
Ovarian Cancer
◽
Recurrent Ovarian Cancer
◽
Open Label
◽
Phase 3
◽
Open Label Phase
Download Full-text
Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO
SSRN Electronic Journal
◽
10.2139/ssrn.3478102
◽
2019
◽
Author(s):
Chiara Cremolini
◽
Carlotta Antoniotti
◽
Daniele Rossini
◽
Sara Lonardi
◽
Fotios Loupakis
◽
...
Keyword(s):
Colorectal Cancer
◽
Randomised Controlled Trial
◽
Metastatic Colorectal Cancer
◽
Controlled Trial
◽
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Randomised Controlled
Download Full-text
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
The Lancet Oncology
◽
10.1016/s1470-2045(21)00090-5
◽
2021
◽
Author(s):
Martin J van den Bent
◽
C Mircea S Tesileanu
◽
Wolfgang Wick
◽
Marc Sanson
◽
Alba Ariela Brandes
◽
...
Keyword(s):
Interim Analysis
◽
Anaplastic Glioma
◽
Open Label
◽
Phase 3
◽
Open Label Phase
Download Full-text
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
The Lancet Oncology
◽
10.1016/s1470-2045(20)30754-3
◽
2021
◽
Vol 22
(4)
◽
pp. 499-511
◽
Cited By ~ 1
Author(s):
Eric P Winer
◽
Oleg Lipatov
◽
Seock-Ah Im
◽
Anthony Goncalves
◽
Eva Muñoz-Couselo
◽
...
Keyword(s):
Breast Cancer
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Open Label
◽
Phase 3
◽
Open Label Phase
Download Full-text
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
The Lancet Oncology
◽
10.1016/s1470-2045(20)30641-0
◽
2021
◽
Vol 22
(2)
◽
pp. 198-211
◽
Cited By ~ 2
Author(s):
Luis Paz-Ares
◽
Tudor-Eliade Ciuleanu
◽
Manuel Cobo
◽
Michael Schenker
◽
Bogdan Zurawski
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Small Cell
◽
Small Cell Lung
◽
First Line
◽
Open Label
◽
Phase 3
◽
Open Label Phase
Download Full-text
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial
The Lancet Oncology
◽
10.1016/s1470-2045(20)30599-4
◽
2021
◽
Vol 22
(2)
◽
pp. 256-266
◽
Cited By ~ 2
Author(s):
François Quénet
◽
Dominique Elias
◽
Lise Roca
◽
Diane Goéré
◽
Laurent Ghouti
◽
...
Keyword(s):
Intraperitoneal Chemotherapy
◽
Cytoreductive Surgery
◽
Hyperthermic Intraperitoneal Chemotherapy
◽
Peritoneal Metastases
◽
Open Label
◽
Phase 3
◽
Open Label Phase
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close